Researchers have found in a new study among patients under 65 years treated with NOACs for nonvalvular atrial fibrillation, ...
Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...
At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...
Older adults with venous thromboembolism (VTE) reported fewer blood clot complications while using apixaban compared to other ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during 3-month trial period. HealthDay News — The risk for clinically relevant bleeding is significantly ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
The use of apixaban (Eliquis; Bristol-Myers Squibb) over rivaroxaban (Xarelto; Bayer/Janssen) in patients with atrial fibrillation (AF) and valvular heart disease is associated with better clinical ...
Using bright X-rays from the Department of Energy's SLAC National Accelerator Laboratory and Lawrence Berkeley National ...
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results